Sage Therapeutic Stock Price, News & Analysis

Sage Therapeutics and Biogen announced that the Phase 3 WATERFALL Study for zuranolone (SAGE-217/BIIB125) in Major Depressive Disorder (MDD) met its primary endpoint. Zuranolone 50 mg showed a significant improvement in depressive symptoms compared to placebo, with a mean change from baseline in HAMD-17 total score at Day 15 of -14.1 versus -12.3 for placebo (p=0.0141). Zuranolone demonstrated a favorable safety profile, with common adverse events being mild to moderate. The U.S. FDA has granted Breakthrough Therapy Designation for zuranolone, indicating its potential as a new treatment option.

Sage Therapeutics (Nasdaq: SAGE) will host the first Sage Science Spotlight webcast on May 20, focusing on SAGE-718, its lead neuropsychiatry product candidate.

The webcast will cover advancements in treating cognitive disorders related to NMDA receptor dysfunction and discuss new data from the PARADIGM Study for patients with mild cognitive impairment due to Parkinson’s disease. Sage will also initiate a Phase 2 study in Huntington’s disease. Expert speakers will include Sage's Chief Research Officer and a leading neurologist.

Access the webcast on Sage's investor page.

Sage Therapeutics reported Q1 2021 results, showcasing advancements in its depression, neurology, and neuropsychiatry franchises. The company highlighted significant clinical data for zuranolone, SAGE-324, and SAGE-718, with ongoing Phase 3 trials anticipated to support potential approvals. Revenue from ZULRESSO reached $1.6 million, a decline from $2.3 million in Q1 2020. R&D expenses decreased to $58.1 million. Despite a net loss of $95.8 million, Sage expects a strong cash position of over $1.7 billion by year-end. The company continues to pursue innovative therapies for brain health disorders.

Sage Therapeutics, a biopharmaceutical company focused on treating brain disorders, will present at two investor conferences in May 2021. The first is the Bank of America Health Care Conference on May 11, 2021, at 10:15 am ET, followed by the RBC Capital Markets Global Healthcare Conference on May 18, 2021, at 8:35 am ET. Live webcasts will be available on the company's investor page, with replays accessible for 30 days. Sage's mission is to develop therapies that improve brain health and transform treatment for depression and neurological disorders.

Sage Therapeutics, Inc. (Nasdaq: SAGE) will host a live webcast on May 4, 2021, at 8:00 a.m. ET to discuss its first quarter 2021 financial results and recent business updates. Investors can access the webcast via the company's investor page. A replay will be available about two hours post-event and archived for 30 days. Sage Therapeutics is dedicated to developing innovative therapies aimed at treating brain disorders, particularly focusing on depression, neurology, and neuropsychiatry.

Sage Therapeutics and Biogen announced positive topline results from the Phase 2 KINETIC Study of SAGE-324 for essential tremor treatment. The study achieved its primary endpoint with a significant reduction in upper limb tremor score, showing a 36% decrease in the SAGE-324 group versus 21% in placebo (P=0.049). Severe tremor patients demonstrated an even greater 41% reduction. Safety profiles were consistent with previous data, and plans for further development of SAGE-324 are underway, reflecting the substantial unmet medical need in treating essential tremor affecting over 6.4 million in the U.S.

Sage Therapeutics (NASDAQ: SAGE) announced its participation in the Stifel 3rd Annual CNS Day fireside chat on March 31, 2021, at 8:00 am ET. This event highlights Sage's commitment to developing innovative therapies for brain disorders. Investors can access a live webcast on the company's investor page, with a replay available two hours post-event and archived for 30 days. Sage Therapeutics focuses on transforming treatment approaches for depression, neurology, and neuropsychiatry, aiming to improve brain health and patient outcomes.

Sage Therapeutics reported 12-month data from the Phase 3 SHORELINE Study evaluating zuranolone for major depressive disorder (MDD). The 30 mg cohort demonstrated favorable safety, with 51% reporting at least one adverse event, consistent with previous studies. 73.5% of patients achieved a clinical response, requiring an average of 2.2 treatments within the year. Interim data from the 50 mg cohort showed 80.5% response rates. Sage aims to provide further data at upcoming conferences, while continuing to assess zuranolone’s long-term efficacy and safety.

Sage Therapeutics (NASDAQ: SAGE) announced the departure of Chief Operating Officer Mike Cloonan, effective May 3, 2021. Cloonan, who has been with the company for four years, expressed intentions to pursue a Chief Executive Officer role in the biopharmaceutical sector. CEO Barry Greene commended Cloonan for his contributions and confirmed that his responsibilities will be temporarily assumed by Greene as Sage continues its growth strategy. The company remains focused on advancing its multiple brain health programs and has no immediate plans to fill the COO position.